ATTAX: A randomised phase II study evaluating tumour response rates of a weekly schedule of docetaxel with cisplatin and 5-FU (wTCF) or with Capecitabine (wTX) in advanced oesophago-gastric cancer.

Trial Profile

ATTAX: A randomised phase II study evaluating tumour response rates of a weekly schedule of docetaxel with cisplatin and 5-FU (wTCF) or with Capecitabine (wTX) in advanced oesophago-gastric cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Capecitabine; Cisplatin; Docetaxel; Fluorouracil
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms ATTAX
  • Most Recent Events

    • 12 Jan 2010 Results presented in the British Journal of Cancer.
    • 29 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top